During this April 2024 briefing to Congressional staff, ASGCT members gave an overview of gene editing techniques and applications, held a discussion about the clinical trials process, and talked about why these technologies can be an important tool for the rare disease patient community.
Speakers included:
-Jeffrey Chamberlain, PhD, University of Washington
-Fyodor Urnov, PhD, University of California Berkley
-Janice Chen, PhD, Mammoth Biosciences
-Matthew Porteus, MD, PhD, Standford University Medical School
-Amy Raymond, PhD, Worldwide Clinical Trials